Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Insider Buying

Caught this at the end of today's trading: https:// more

More good results

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) (  rate and reply

Brascan Announces Agreement to Acquire REE Claims

Balbir Johal, CEO of Brascan, stated, “We are excited to expand into battery metals by our first acquisition of this REE property in Ontario, Canada. Exploration to begin shortly.” Mr. Johal further said: “Brascan intends to build a portfolio of highly prospective lithium properties in Canada and Brazil.” more

RE:RE:RE:WTH ? Happened today ?

New suitor reported again. Short term price changes are just games with the shorts, they have beat this thing hard and won't let it alone. No matter a BO is a set price. This was designed to more

RE:RE:WTH ? Happened today ?

I also see there was a shite load of insider sales in November , That is not a good sign.  rate and reply

RE:WTH ? Happened today ?

Aurinia announced a possible large financing Friday after the close.  Obviously, if they are doing a financing, they aren't going to be bought out.  The price simply dropped back to more

WTH ? Happened today ?

I don't get it  ?  rate and reply

RE:Still no offer

I'm patient but hope before the end of the year. Lawyers get payed by the hour, LOL  rate and reply

Still no offer

I think we should get an offer has been in play for a few days now...I guess lots of negotiating going on behind the scene...  rate and reply

Thematica Insights Report and Investor Guide

Thematica Report: Investing in undervalued stocks

The Market Herald launches Thematica's latest report: Unlocking the Advantages of Undervalued Stocks. Download it today!


Now talk of multiple biders @ +$40  rate and reply


Yes that would be great :-)  rate and reply


RBC upped their target price from $23 to $34 US today. I'd be pretty happy with that price on a takeover.  rate and reply


Current Sp was heavily manipulated by short sellers. Treatment is est @ $62000 yr but Ive also seen $90000as a price. Gets big fast with decent market penetration, say 30% of 300,000 and that' more


The AUPH stock price was $22 before the rumour came out on Friday.  A 50% premium would get get it to $33.  I doubt an offer would be for much more than that.  Maybe $35. more


No one here? I see $45-$50 buyout but hope for a staight share for share with Bristol as they have pulled back. Thoughts?  rate and reply


We will see the price.  rate and reply

RE:Decent Q2 results

Same opinion here. Several valuable patents, giving them access to the market for rare diseases. Further, they already had the success with FDA on their product, and started to commercialize it in more


Wait. If we can get over $20.50 this will really fly.  rate and reply

Decent Q2 results

Looks like they are on their way to some great future revenue....unfortuneatly we will now have to trade only on nasdaq  rate and reply

Insider buying

Lots of insider buying recently....good sign and could account for the recent run up.....Once they start actually showing some decent revenue this will be well over $20 a share....just taking a more

RE:Aurinia Reports First Quarter 2021 Financial Results

I see the market was very disappointed with the progress to commercialize the drug. Sure hope they make better progress for Q2  rate and reply